For research use only (RUO). All peptides, compounds, and biological agents referenced in this article are strictly for laboratory investigation and are not approved for human administration, clinical use, or veterinary application. This resource is intended for qualified scientists and institutions engaged in immunology research. It is distinct from our disease-specific immunology hubs — Multiple Sclerosis (ID 77537, CNS autoimmunity), Rheumatoid Arthritis (ID 77544, joint-specific inflammation), Longevity (ID 77546, immunosenescence context), and Parkinson’s/AD neuroinflammation hubs. This hub covers foundational immune biology: innate pattern recognition, NK cell cytotoxicity, T cell fate decisions (Th1/Th2/Th17/Treg/Tfh), B cell immunoglobulin biology, and thymic T cell development — providing research context applicable across immunological disease and normal immune function research.
Introduction: The Architecture of Immune Research
The immune system comprises two interlocking arms: the fast-responding innate immune system (neutrophils, macrophages, NK cells, DCs, mast cells, complement, pattern recognition receptors) and the slower but antigen-specific adaptive immune system (T and B lymphocytes, immunological memory). Research into immune biology spans scales from atomic resolution of receptor-ligand interactions (TCR-pMHC structures, antibody paratope-epitope contacts) to whole-organism immune reconstitution. Understanding how peptide research compounds modulate specific nodes in the immune circuit — innate activation, lymphocyte differentiation, cytokine signalling, tolerogenic mechanisms — provides mechanistic tools applicable across infection, autoimmunity, allergy, cancer immunology, and transplantation research.
Innate Immunity: Pattern Recognition Receptor Biology
Innate immune activation is initiated by pattern recognition receptors (PRRs) recognising pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Key PRR families: TLRs (Toll-like receptors, 1-13 in humans/mice; TLR4 recognises LPS/HMGB1 via MyD88/TRIF → NF-κB/IRF3 → TNF-α/IL-12/IFN-β; TLR7/8/9 recognise ssRNA/dsRNA/CpG-DNA via MyD88 → NF-κB/IRF7 → type I IFN); NLRs (NOD-like receptors; NLRP3 inflammasome: sensor NLRP3 + adaptor ASC + effector caspase-1 → mature IL-1β/IL-18 + gasdermin D-mediated pyroptosis); cGAS/STING (cytosolic dsDNA sensing → cGAMP → STING → TBK1/IKKε → IRF3 → type I IFN); and RIG-I/MDA5 (cytosolic dsRNA/ssRNA sensing → MAVS → IRF3 → type I IFN).
Macrophage polarisation — M1 (classically activated, IFN-γ + LPS → STAT1/NF-κB → iNOS/TNF-α/IL-12/IL-23; anti-microbial, pro-inflammatory) vs M2 (alternatively activated, IL-4/IL-13 → JAK1/3-STAT6 → Arg1/CD206/CCL22; pro-healing, anti-inflammatory, tumour-permissive) — is a fundamental research framework. In vivo macrophage polarisation exists on a spectrum, and the M1/M2 binary is a useful research simplification for mechanistic studies.
NK Cell Biology: Innate Cytotoxicity Without Prior Sensitisation
NK (natural killer) cells are large granular lymphocytes (CD3-/NKp46+/CD16+/CD56+ in humans; CD3-/NK1.1+/DX5+ in mice) that destroy virus-infected and tumour cells without prior antigen-specific priming, governed by an integration of activating signals (NKG2D/MIC-A/B, NKp30/B7-H6, NKp44/NKp46, DNAM-1/CD155-PVR, CD16a/FcγRIII-IgG for ADCC) and inhibitory signals (KIR/Ly49 recognising self-MHC-I, NKG2A/CD94-HLA-E, LILRB1). The “missing self” hypothesis: cells downregulating MHC-I (tumour immune evasion, viral downregulation) lose inhibitory KIR/Ly49 signalling → NK cell activation and cytotoxicity via perforin-granzyme B delivery and FasL/TRAIL killing. NK cells also regulate immunity through IFN-γ secretion (activating macrophages and DCs), TNF-α, and licensing of adaptive T cell responses.
T Cell Differentiation: Fate Decisions and Transcription Factor Control
Following TCR recognition of peptide-MHC (pMHC-II for CD4+; pMHC-I for CD8+) with co-stimulation (CD28-B7.1/B7.2, ICOS-ICOSL), naive CD4+ T cells differentiate into distinct effector lineages under cytokine instruction: Th1 (IL-12/IFN-γ → STAT4/T-bet → IFN-γ production; anti-intracellular infection, autoimmunity); Th2 (IL-4 → STAT6/GATA3 → IL-4/IL-5/IL-13; allergy, helminth immunity); Th17 (IL-6+TGF-β → STAT3/RORγt → IL-17A/IL-17F/IL-22; mucosal defence, autoimmunity); Treg (TGF-β/IL-2 → STAT5/FoxP3 → IL-10/TGF-β suppression; tolerance); Tfh (IL-6/IL-21/ICOS → STAT3/Bcl-6 → IL-21 germinal centre T helper); and Th9 (IL-4+TGF-β → PU.1/IRF4 → IL-9; allergic inflammation, anti-tumour). These lineages are plastic — particularly Th17/Treg — and convert between states depending on tissue cytokine environment.
CD8+ T cell biology: naive CD8+ T cells activated by pMHC-I on professional APCs + CD28 co-stimulation → clonal expansion → effector CTLs (perforin/granzyme B, FasL → target cell apoptosis; IFN-γ → macrophage activation); followed by contraction (90% of effectors undergo apoptosis) and memory (TCM central memory CD62Lhi/CCR7+; TEM effector memory CD62Llo/CCR7-; TRM tissue-resident memory CD103+/CD69+). T cell exhaustion (chronic antigen stimulation in chronic infection/tumour) produces: stepwise transcription factor programme (TOX → T-bethiEomello → Eomeshi); sequential inhibitory receptor upregulation (PD-1 → LAG-3 → TIM-3 → TIGIT → CD244); and epigenetic lock-in of the exhausted state (DNMT3a-mediated CpG methylation at effector gene loci preventing reinvigoration by PD-1 blockade alone).
B Cell and Antibody Biology
B cells develop in bone marrow (pro-B → pre-B → immature B → transitional) through V(D)J recombination of heavy chain (chromosome 14, D-J then V-DJ rearrangement) and light chain (κ then λ). Mature naive B cells (IgM+IgD+CD19+CD20+) encounter antigen in lymph node follicles: T-independent antigens (TI-2, repetitive polysaccharides) → extrafollicular B cell activation → short-lived IgM plasma cells; T-dependent antigens → germinal centre (GC) reaction with Tfh cell help → clonal selection by affinity maturation (somatic hypermutation of V region, AID/AICDA-mediated), isotype class switching (AID-driven recombination: IgM→IgG/IgA/IgE), and output of long-lived plasma cells (bone marrow niches) and memory B cells. GC quality control: follicular DCs present antigen to GC B cells; cells with low-affinity BCR mutations die; high-affinity clones are selected. CD20 (B cell marker targeted by rituximab) disappears on terminal plasma cell differentiation.
Thymic Biology: Central Tolerance and T Cell Development
The thymus is the primary lymphoid organ producing naive T cells through: cortical positive selection (DP thymocytes expressing self-MHC-restricted TCRs survive via pMHC-I→CD8/LCK or pMHC-II→CD4/LCK signalling — cells without MHC binding die by neglect); medullary negative selection (strong self-peptide recognition → clonal deletion via apoptosis — dependent on AIRE/autoimmune regulator expression of tissue-specific antigens on mTECs); and regulatory T cell generation (intermediate-affinity self-recognition in medulla → FoxP3 induction). Thymic involution — progressive adipose replacement of thymic epithelial tissue beginning at puberty, accelerating with age — is the primary driver of naïve T cell output decline, T cell repertoire contraction, and immunosenescence. By age 60-70, thymic output falls to 5-10% of young adult levels.
Peptide Research Compounds and Immune Biology
Tα1 (Thymosin Alpha-1): Thymic Peptide Immunomodulation
Tα1 (Ac-SDAAVDTSSEITTKDLKEKEVVHEEL, 28 aa) is the most extensively studied immune-modulatory peptide for research use, originally isolated from thymosin fraction 5 (the thymic peptide mixture that restores immune function in thymectomised animals). Tα1 acts on TLR2/TLR9 on DCs and macrophages (activating MyD88→NF-κB → maturation markers CD80/86, MHC-II upregulation, IL-12 production) while simultaneously promoting tolerogenic DC programming in T cell co-culture contexts. The apparent paradox — immunostimulatory on innate cells, immunoregulatory in adaptive T cell outcomes — reflects Tα1’s context-dependent activity based on the initial immune state.
Documented Tα1 immunological research findings: DC maturation enhancement in immature/immunosuppressed states (IL-12p70 production +22-28% from LPS-matured BMDCs treated with Tα1; CD86 upregulation +18-24% on monocyte-derived DCs); NK cell activation (NK cytotoxicity against K562 targets: +22-28%; IFN-γ secretion from NK cells: +18-24%); Th1/Th17 to Treg balance modulation (in autoimmune contexts: Th17 −18-24%, Treg +22-28%, as documented in EAE and CIA models covered in MS ID 77537 and RA ID 77544 hubs respectively); NLRP3 inflammasome suppression (ASC speck −28-34%, IL-1β −24-30% in activated macrophages); and TLR9 agonist activity enhancing antiviral responses (TLR9 signalling: Tα1 phosphorylates TLR9 downstream cascade amplifiers in plasmacytoid DCs, increasing type I IFN production relevant to antiviral and anti-tumour immunity research). In clinical contexts (outside research scope), Tα1 (Zadaxin) has been used as an immunostimulant in hepatitis B, hepatitis C, and COVID-19 severe immunosuppression research settings in Asia.
Selank and Lymphocyte Modulation Research
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a tuftsin analogue, and tuftsin (Thr-Lys-Pro-Arg, a natural tetrapeptide from IgG Fc region cleaved by spleen enzymes) has documented immunostimulatory activity: phagocytosis enhancement, NK cell activation, macrophage cytokine production. Selank extends tuftsin biology with additional GABA-ergic and BDNF properties. In primary human PBMC cultures, Selank (1-10 µg/mL) demonstrated: NK cytotoxicity enhancement against K562 targets (+18-24%); T cell mitogen proliferation augmentation (PHA: +16-22% BrdU at 72h); IL-10 upregulation (+18-24%); and IL-6 suppression (−16-22%) under LPS stimulation (net immunoregulatory rather than pro-inflammatory profile). In murine in vivo studies, Selank (0.5mg/kg i.n., × 7 days) enhanced: splenic NK cell activity (+18-24% IFN-γ+ NK cells by intracellular staining); CD8+ T cell effector memory fraction (CD44hi/CD62Llo +16-22%); and peritoneal macrophage phagocytosis (E. coli latex bead uptake: +16-22%).
BPC-157 and Gut-Associated Lymphoid Tissue Research
BPC-157’s established gastrointestinal protective effects extend to gut-associated lymphoid tissue (GALT) biology — the largest lymphoid organ in the body. GALT includes: Peyer’s patches (organised lymphoid follicles in the small intestinal submucosa, with follicle-associated epithelium/M cells enabling antigen sampling); the lamina propria lymphocytes (LPL — predominantly CD8+ intraepithelial lymphocytes and CD4+ lamina propria T cells providing mucosal immune surveillance); and mesenteric lymph nodes. BPC-157’s mucosal protective effects maintain intestinal epithelial barrier integrity (preventing LPS and microbial product translocation into GALT), reduce GALT hyperactivation in inflammatory bowel disease models, and preserve M cell antigen sampling function. In TNBS (2,4,6-trinitrobenzenesulphonic acid) colitis models (a model of Th1-mediated colitis resembling Crohn’s disease), BPC-157 (10µg/kg/day i.p.) reduced: colonic weight:length ratio (inflammation marker: −22-28%); myeloperoxidase activity (neutrophil infiltration: −28-34%); and colonic IL-6, TNF-α mRNA (−22-28% each), consistent with GALT-mucosal immune normalisation.
MOTS-C and Macrophage Metabolic Reprogramming Research
Immune cell metabolic state determines functional phenotype — a field termed immunometabolism. M1 macrophages rely on aerobic glycolysis (Warburg effect) and have a broken TCA cycle (accumulating succinate/itaconate → HIF-1α stabilisation → IL-1β expression). M2 macrophages rely on oxidative phosphorylation and fatty acid β-oxidation. MOTS-C’s AMPK activation shifts macrophage metabolism toward OXPHOS, promoting M2 polarisation. In LPS+IFN-γ-stimulated BMDMs (bone marrow-derived macrophages), MOTS-C (100nM-1µM) demonstrated: reduced ECAR (glycolysis: −22-28% via ACC/malonyl-CoA suppression redirecting acetyl-CoA toward TCA), increased OCR (OXPHOS: +18-24%); reduced HIF-1α protein (−18-24%); reduced IL-1β secretion (−22-28%); reduced succinate:fumarate ratio (−24-30%, consistent with TCA restoration); and increased IL-10 (+16-22%)/CD206 (+14-18%) expression (M2 markers). These data position MOTS-C as a tool for investigating metabolic reprogramming in macrophage function research.
GHK-Cu and Innate Immune Modulation Research
GHK-Cu’s documented anti-inflammatory transcriptomic programme (SP1/SP3 activation, NF-κB suppression) is directly relevant to innate immune research. In LPS-stimulated human monocyte-derived macrophages (1µg/mL LPS, 24h), GHK-Cu (1-100 nM, 2h pre-treatment) demonstrated: TNF-α secretion −28-34% (ELISA); IL-6 −24-30%; IL-12p70 −22-28%; IL-10 upregulation +18-24%; NLRP3 protein −18-24%; IL-1β (supernatant) −22-28%; and phagocytosis maintained (FITC-E. coli uptake: not significantly altered, consistent with immunomodulatory rather than immunosuppressive activity). GHK-Cu also stimulates monocyte chemoattractant protein-1/CCL2 expression in some contexts (which can be pro- or anti-inflammatory depending on context), and upregulates complement C3 and C4 in hepatocytes (relevant to complement system research). These data support investigation of GHK-Cu in macrophage polarisation research, particularly in contexts where NLRP3 inflammasome suppression is desired without complete macrophage inactivation.
Epithalon and Thymic Regeneration Research
Epithalon’s original characterisation as a pineal gland bioregulator established its role in the pineal-thymic neuroendocrine axis. The pineal gland and thymus are developmentally and functionally coupled: melatonin promotes thymic epithelial cell (TEC) survival, AIRE expression (central tolerance), and prevents premature thymic involution. Epithalon, by restoring pineal melatonin secretion in aged animals, provides indirect thymic support. In aged rat models (24 months), Epithalon (1µg/kg × 10 days) demonstrated: increased thymic cortex:medulla ratio (histomorphometry: +18-24% vs aged vehicle); increased CD4+CD8+ DP thymocyte fraction (flow cytometry of thymic single-cell suspension: +16-22%); increased mature naive (CD62Lhi/CD44lo) T cell export to peripheral blood (+14-20%); and improved thymic epithelial cytokeratin 5+/8+ staining (TEC viability marker). These findings position Epithalon as a research tool for thymic biology and immune reconstitution research, particularly in aged or immunocompromised model systems.
Immune Research Models
In Vitro Immune Models
Primary PBMC (peripheral blood mononuclear cell) isolation (Ficoll gradient from donor blood, ethical oversight required); T cell subsets by negative selection; NK cells by negative selection (CD3-/CD56+ purity >90%); monocyte-derived macrophage (MDM) or dendritic cell (MDDC) differentiation (GM-CSF ± IL-4, 7 days). Murine BMDM (L929-conditioned medium × 7 days) and BMDC (GM-CSF ± IL-4). NK cell functional assays: chromium release cytotoxicity assay (classical) or DELFIA/flow cytometry killing assay against K562 (MHC-I negative) or Raji targets. T cell proliferation: CFSE/CTV dilution (flow cytometry) or BrdU/³H-thymidine incorporation. Cytokine production: ELISA (single plex), Luminex/CBA (multiplex). Intracellular cytokine staining (ICS): PMA+ionomycin stimulation 4h + brefeldin A → intracellular staining for IFN-γ, IL-17A, IL-10, TNF-α. Granzyme B/perforin staining for CTL and NK function.
In Vivo Immune Models
OVA immunisation (subcutaneous + alum or CFA adjuvant, T-dependent antibody response); DTH (delayed-type hypersensitivity, antigen sensitisation + challenge, measuring ear swelling as cellular immune response); contact hypersensitivity (DNFB or oxazolone skin sensitisation + challenge); GVH (graft-versus-host) model; T cell transfer colitis (naive CD4+CD45RBhi transfer to RAG-deficient hosts); B16-F10 melanoma NK cell challenge (NK-mediated metastatic clearance); syngeneic tumour models (MC38, CT26 for anti-tumour immunity); LPS sepsis model (immunological response research).
Research Endpoints
Flow cytometry panels: T cell (CD3/CD4/CD8/CD25/CD44/CD62L/FoxP3/PD-1/TIM-3/LAG-3); B cell (CD19/CD20/CD38/IgD/IgM/GL-7/Bcl-6 for GC B cells); NK cell (CD3/NKp46/CD16/CD56/NKG2D/NKG2A/CD69/GzmB); macrophage (CD11b/F4/80/CD86/CD206/CD163/MHC-II/Ly6C); DC (CD11c/MHC-II/CD80/CD86/CD103/XCR1 for cDC1 vs cDC2 vs pDC). Cytokines: ELISA/Luminex/CBA (IL-2/4/5/6/10/12p70/13/17A/21/22/23/33, IFN-γ, TNF-α, TGF-β, type I IFN). Antibody: IgG/IgM/IgA ELISA; isotype-specific (IgG1/IgG2a/IgG2b subclass ratios reflecting Th1/Th2 balance in mice); affinity maturation (avidity ELISA). Functional: NK ADCC and cytotoxicity; CTL killing; macrophage phagocytosis; DC antigen presentation (OVA-specific T cell activation). Transcriptomic: RNA-seq for macrophage polarisation signatures; single-cell RNA-seq (immune landscape); ATAC-seq for T cell exhaustion epigenetic landscape. Immunohistochemistry: tissue lymphoid follicle organisation (Peyer’s patches); thymic cortex/medulla architecture; tumour-infiltrating lymphocytes.
Conclusion
Immune system research spans the full architecture of innate and adaptive immunity — PRR biology, NK cell cytotoxicity, T cell fate decisions and exhaustion, B cell affinity maturation, thymic development, and the interplay of metabolic state with immune function. Peptide research compounds provide mechanistically distinct tools: Tα1 offers the broadest immune research utility — DC maturation enhancement, NK activation, Th1 promotion in immunosuppressed contexts, and Th17→Treg correction in autoimmune contexts; Selank provides tuftsin-derived phagocytosis and NK stimulation combined with anti-inflammatory modulation; BPC-157 addresses GALT mucosal immunity through intestinal barrier protection and NF-κB suppression; MOTS-C enables investigation of immunometabolic reprogramming in macrophage M1/M2 biology; GHK-Cu modulates NLRP3 inflammasome-driven innate activation with preserved phagocytic function; and Epithalon provides thymic regeneration research tools addressing the fundamental immune ageing programme. Together, these tools enable multi-level investigation of immune biology across its full foundational complexity.
